{
    "clinical_study": {
        "@rank": "75811", 
        "brief_summary": {
            "textblock": "This trial is in high risk patients to determine the safety, tolerance and efficacy of\n      posaconazole (POZ) vs. fluconazole in the prophylaxis against development of invasive fungal\n      infections (IFI)."
        }, 
        "brief_title": "Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease", 
        "completion_date": "December 2003", 
        "condition": "Mycoses", 
        "condition_browse": {
            "mesh_term": [
                "Graft vs Host Disease", 
                "Mycoses"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed to determine the safety, tolerance and efficacy of POZ used as\n      prophylaxis of IFI in high-risk subjects with Grade II-IV acute graft vs. host disease\n      (GVHD) or extensive chronic GVHD. The primary objective is to assess the efficacy of\n      SCH56592 vs fluconazole in preventing proven or probable IFI within the time period from\n      randomization to 16 weeks after the start of treatment with study drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hematopoietic progenitor cell transplant subjects with chronic or Grade II-IV acute\n             GVHD being treated with high dose immunosuppressive therapy.\n\n          -  One of the following to the subject's prior immunosuppressive regimen:\n\n               1. at least 1mg per kg per day of methylprednisolone or equivalent,\n\n               2. Antithymocyte globulin (ATG) for the therapy of acute GVHD,\n\n               3. Tacrolimus, mycophenolate mofetil, or other steroid-sparing immunosuppressive\n                  regimen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "600", 
        "firstreceived_date": "May 1, 2002", 
        "id_info": {
            "nct_id": "NCT00034645", 
            "org_study_id": "C98316", 
            "secondary_id": "C/I98-316"
        }, 
        "intervention": {
            "intervention_name": "Posaconazole oral suspension", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Posaconazole"
        }, 
        "keyword": [
            "Allogenic Stem cell transplantation", 
            "Fungal infections"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "removed_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Australia", 
                "Austria", 
                "Brazil", 
                "Canada", 
                "Czech Republic", 
                "Denmark", 
                "Finland", 
                "France", 
                "Germany", 
                "Greece", 
                "Hungary", 
                "Italy", 
                "Mexico", 
                "Netherlands", 
                "Peru", 
                "Poland", 
                "Portugal", 
                "Saudi Arabia", 
                "Singapore", 
                "South Africa", 
                "Spain", 
                "Sweden", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034645"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 1998", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }, 
    "geocoordinates": {}
}